At Medis we believe that QFR® is the future in angiography, QFR® is a non-non-invasive angiography based physiologic assessment of the presence and extent of coronary artery disease. QFR® provides the healthcare professional with more extensive and quantitative physiologic imaging results to support the patient’s diagnosis and better inform the patient’s treatment. In order to strengthen our case for QFR®, Medis is participating in a number of clinical trials.
One of those clinical trials is the FIRE trial, the trial is organized by and run from Ferrara University in Italy under the leadership of Dr. Simone Biscaglia (PI) and Prof. Gianluca Campo (Study chair).
This “Functional versus Culprit-only Revascularization in Elderly Patients with Myocardial Infarction and Multivessel Disease (FIRE) trial” was designed to test whether a complete revascularization based on coronary physiology may improve prognosis compared to culprit only revascularization in older adults (≥75 years) with myocardial infarction (STEMI or NSTEMI) and multivessel disease. The trial will include 1400 patients from 25 participating sites in Italy and Spain.
Interested to learn more about the use of coronary physiology and QFR®, click here
For more information on the trial, see www.thefiretrial.com
